<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is the causal agent in the etiology of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> and is also associated with multiple human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including Hodgkin's and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and posttransplantation <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e>, as well as <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> of other tissues </plain></SENT>
<SENT sid="1" pm="."><plain>A causal relationship of EBV to these latter <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> remains controversial, although the episomic EBV genome in most of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> is clonal, suggesting <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> very early in the development of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and a possible role for EBV in the genesis of these diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, the prognosis of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> is invariably poor when EBV is present, compared to their EBV-negative counterparts </plain></SENT>
<SENT sid="3" pm="."><plain>The physical presence of EBV in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> represents a potential "<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific" target for therapeutic approaches </plain></SENT>
<SENT sid="4" pm="."><plain>While treatment options for other types of <z:e sem="disease" ids="C0019372" disease_type="Disease or Syndrome" abbrv="">herpesvirus infections</z:e> have evolved and improved over the last two decades, however, therapies directed at EBV have lagged </plain></SENT>
<SENT sid="5" pm="."><plain>A major constraint to pharmacological intervention is the shift from lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> to a latent pattern of gene expression, which persists in those <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> associated with the virus </plain></SENT>
<SENT sid="6" pm="."><plain>In this paper we provide a brief account of new virus-targeted therapeutic approaches against EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>